Oncode Investigator Madelon Maurice receives KWF funding for innovative SureTAC technology
KWF has announced that Laigo Bio, a public-private collaboration between Oncode Bridge Fund and Argobio, will receive 1.2 million euros subsidy.
KWF has announced that Laigo Bio, a public-private collaboration between Oncode Bridge Fund and Argobio, will receive 1.2 million euros subsidy.
Chiome Bioscience Inc. announced that the first patient has been dosed with CBA-1535 in a Phase I clinical trial.
The first part of the trial will evaluate the safety tolerability, pharmacokinetics, and identification of biomarker for the solid tumor patients . In the expansion part, exploratory efficacy will be evaluated in combination with cancer immunotherapy agent Pembrolizuma.
This first in human study is conducted at National Cancer Center Hospital and Shizuoka Cancer Center (Japan).
Tribodies combining blockers for PD-1, PD-L1 and LAG-3 showed enhanced activity on activating lymphocytes as compared to a mix of the parental mAbs, with lower toxicity on normal tissue.
Chiome Bioscience Inc., announced that it has submitted an initial application for a Phase I study on CBA-1535 to the Pharmaceuticals and Medical Devices Agency (PMDA, Japan) on February 16, 2022.
Chiome Bioscience Inc. announced submittion for a Phase I study on CBA-1535 (TB535) Read More »
Laigo Bio is a targeted protein degradation biotech with programs in oncology and neurological disorders
Oncode Institute and ArgoBio launch Laigo Bio Read More »
The 2nd of February 2021, SVF was granted a U.S patent (No: 10,905,760) covering chimeric genes and polypeptides that are useful for the generation, enhancement, or improvement of the immune response to chronic hepatitis B and D virus infections.
Under this agreement, Biotecnol divested from it’s immuno-oncology pipeline and respective technologies (including Tb535H, and Trisoma®. Chiome will continue research and clinical development for Tb535H. In addition, Chiome will continue generating new immune-oncology products using Biotecnol’s Trisoma® technology. Financial details were not disclosed
Biotecnol and Chiome Bioscience have entered into an asset purchase agreement. Read More »